Hyperion DeFi Inc (HYPD)
Hyperion DeFi, Inc. is a common stock listed on the NASDAQ under the symbol HYPD. The company is an ophthalmic technology business focused on developing and commercializing eye-care solutions in the United States. Its portfolio includes Optejet, a topical ophthalmic medication dispensing platform. Hyperion DeFi also maintains licensing and development arrangements related to MicroPine, MicroLine, and Mydcombi across multiple markets, including the United States, Canada, China, and South Korea, as well as a co-development agreement with Formosa Pharmaceuticals for clobetasol propionate ophthalmic suspension for acute dry eye disease in the U.S. Formerly known as Eyenovia, Inc., the company adopted its current name in July 2025. It was founded in 2014 and is based in New York, New York.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-HYPD
|
$4
|
2.0% Upside
|
Fair
|
$9.82
|
150.6% Upside
|
Bargain
|
Good
|
0.0%
|
November 18, 2026
|
0.5x
|
38.5x
|
60.915 M
|
53.197 M
|
14.2%
|
88.7%
|
-0.8
|
13.4%
|
78.2%
|
